Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.JAMA Oncol. 2017; 3: 1335-1342
- The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors.Pancreas. 2020; 49: 863-881
- Lloyd R.V. Osamura R.Y. Kloppel G. WHO classification of tumours of endocrine organs. 4th edition. IARC, Lyon2017
- Positional cloning of the gene for multiple endocrine neoplasia-type 1.Science. 1997; 276: 404-407
- UMD-MEN1 database: an overview of the 370 MEN1 variants present in 1676 patients from the french population.J Clin Endocrinol Metab. 2019; 104: 753-764
- MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients.BMC Med. 2016; 14: 182
- Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.World J Surg. 2010; 34: 249-255
- Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).J Clin Endocrinol Metab. 2012; 97: 2990-3011
- The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors.Pancreas. 2020; 49: 1-33
- ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.Neuroendocrinology. 2016; 103: 153-171
- Guidelines. NCCN Guidelines Version 1.2022 Neuroendocrine Tumors of the Pancreas (Well-Differentiated Grade 1/2). National Comprehensive Cancer Network (NCCN).(Accessed)
- Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and nonfunctioning pancreatic and duodenal neuroendocrine neoplasia within the men1 syndrome - an international consensus statement.Neuroendocrinology. 2021; 111: 609-630
- Molecular Imaging of Neuroendocrine Neoplasms.J Clin Endocrinol Metab. 2022; 107: e2662-e2670
- Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.Eur J Cancer. 2021; 146: 56-73
- Risk factors for complications after surgery for pancreatic neuroendocrine tumors.Surgery. 2022; 172: 127-136
- Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis.HPB (Oxford). 2017; 19: 310-320
- Systematic review of active surveillance versus surgical management of asymptomatic small nonfunctioning pancreatic neuroendocrine neoplasms.Br J Surg. 2017; 104: 34-41
- Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours.Br J Surg. 2022; 109: 733-738
- Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA).Br J Surg. 2021; 108: 888-891
- Implementation of Current ENETS Guidelines for Surgery of Small (</=2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry.World J Surg. 2019; 43: 175-182
- The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.Surgery. 2019; 166: 15-21
- Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life.Surgery. 2019; 166: 157-163
- Prognosis of sporadic resected small (</=2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.HPB (Oxford). 2018; 20: 251-259
- Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors.World J Gastroenterol. 2017; 23: 3092-3098
- Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor.Surgery. 2011; 150: 75-82
- Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study.Neuroendocrinology. 2018; 107: 375-386
- Reliability of preoperative pancreatic neuroendocrine tumors grading on endoscopic ultrasound specimens: a systematic review with meta-analysis of aggregate and individual data.Gastrointest Endosc. 2022; S0016-5107: 01831-01834
- Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors.Ann Surg Oncol. 2021; 28: 1614-1624
- Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.Gut. 2020; 69: 877-887
- Recurrent loss of heterozygosity in pancreatic neuroendocrine tumors.Am J Surg Pathol. 2022; 46: 823-831
- DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.Science. 2011; 331: 1199-1203
- Whole-genome landscape of pancreatic neuroendocrine tumours.Nature. 2017; 543: 65-71
- Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.Nat Commun. 2015; 6: 7538
- Prognostic significance of altered ATRX/DAXX gene in pancreatic neuroendocrine tumors: a meta-analysis.Front Endocrinol (Lausanne). 2021; 12: 691557
- Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.Gut. 2022; 71: 961-973
- Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.Gastroenterology. 2014; 146 (e455): 453-460
- Alternative lengthening of telomeres and loss of DAXX/ATRX Expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors.Clin Cancer Res. 2017; 23: 600-609
- Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration.Diagn Cytopathol. 2020; 48: 308-315
- Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.Endocr Pathol. 2022; 33: 115-154
- Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.Nat Med. 2019; 25: 1260-1265
- Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.J Pathol. 2022; 256: 143-148
- Consensus on biomarkers for neuroendocrine tumour disease.Lancet Oncol. 2015; 16: e435-e446
- A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.Ann Oncol. 2020; 31: 202-212
- Blood molecular genomic analysis predicts the disease course of gastroenteropancreatic neuroendocrine tumor patients: a validation study of the predictive value of the NETest.Neuroendocrinology. 2021; 111: 586-598
- Dual-tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 nonfunctioning pancreatic neuroendocrine tumors: a single-center retrospective evaluation of 124 nonmetastatic resected cases.Neuroendocrinology. 2022; 112: 143-152
- Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging.Eur Radiol. 2017; 27: 1748-1759
- A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors.Clin Cancer Res. 2019; 25: 584-594
- Preoperative prediction of pancreatic neuroendocrine neoplasms grading based on enhanced computed tomography imaging: validation of deep learning with a convolutional neural network.Neuroendocrinology. 2020; 110: 338-350
- Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance.Eur J Nucl Med Mol Imaging. 2021; 48: 4002-4015
- Diagnosing nonfunctional pancreatic NETs in MEN1: The Evidence Base.J Endocr Soc. 2018; 2: 1067-1088
- Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort.Neuroendocrinology. 2021; 111: 705-717
- Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?.World J Surg. 2017; 41: 2026-2032
- Paediatric and young adult manifestations and outcomes of multiple endocrine neoplasia type 1.Clin Endocrinol (Oxf). 2019; 91: 633-638
- MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'etude des Tumeurs Endocrines.J Clin Endocrinol Metab. 2015; 100: 1568-1577
- Initiating pancreatic neuroendocrine tumour (pNET) screening in young MEN1 patients: results from the DutchMEN Study Group.J Clin Endocrinol Metab. 2021; 106: 3515-3525
- Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.J Clin Endocrinol Metab. 2022; 107: e2056-e2064
- The Impact of (68)Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours.Front Endocrinol (Lausanne). 2021; 12: 654975
- Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.Ann Surg. 2018; 267: 352-356
- Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small </=2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.Ann Surg. 2018; 268: 158-164
- Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.J Clin Endocrinol Metab. 2017; 102: 3795-3805
- Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group.Ann Surg. 2018; 267: 1155-1160
- Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms </=2 cm in MEN1 Patients.Neuroendocrinology. 2016; 103: 779-786
- Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.Endocrine-related cancer. 2020; 27: R145-R161
- Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.Mod Pathol. 2012; 25: 1033-1039
- A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.J Clin Endocrinol Metab. 2021; 106: e4969-e4980
- Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).Endocrine. 2016; 52: 488-494
- Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.J Clin Endocrinol Metab. 2017; 102: 1926-1933
- EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: A systematic review and meta-analysis.Endosc Ultrasound. 2022; 11: 170-185
- Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms.Dig Endosc. 2020; 32: 1031-1041
- Implementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States.Adv Radiat Oncol. 2022; 7: 100953
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med. 2014; 371: 224-233
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.Endocrine-related cancer. 2016; 23: 191-199
- Chemoprevention with Somatuline(c) Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).World J Surg. 2019; 43: 831-838
- Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.Surgery. 2012; 152: 1068-1077
- Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.Endocrinology. 2016; 157: 1789-1798
- Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.Clin Endocrinol. 2014; 80: 850-855
- The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.Clin cases mineral bone Metab. 2017; 14: 123-130
- Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.J Clin Endocrinol Metab. 2020; 105
- Update on the clinical management of multiple endocrine neoplasia type 1.Clin Endocrinol (Oxf). 2022; 97: 409-423
- Multiple Endocrine Neoplasia Type 1.in: Feingold K.R. Anawalt B. Boyce A. Endotext. MDText.com, Inc.Copyright, South Dartmouth (MA)2000 (© 2000-2022, MDText.com, Inc.)
- p27 Loss is associated with poor prognosis in gastroenteropancreatic neuroendocrine tumors.Cancer Res Treat. 2014; 46: 383-392
- Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.Ann Surg. 2021; 274: e949-e956
- Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.J Clin Oncol. 2010; 28: 245-255
- Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).Clin Cancer Res. 2020; 26: 5943-5951
- Loss of chromatin-remodeling proteins and/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times.Gastroenterology. 2018; 154: 2060-2063 e2068
- Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors.Pancreas. 2020; 49: 514-523
- Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.Am J Surg Pathol. 2012; 36: 173-184
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
